Screener
Summit Therapeutics SMMT Preferred Stock, Shares Authorized
Preferred Stock, Shares Authorized at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.
The source filing: Summit Therapeutics’s 10-Q, filed April 30, 2026.
- Filed
- Apr 30, 2026, 5:00 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001599298-26-000039
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | 101,924 | 92,322 |
| Commitments and contingencies (Note 12) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.01 par value, 20,000,000 shares authorized; none issued and outstanding at March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.01 par value: 1,000,000,000 shares authorized; 776,017,474 and 775,371,200 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively | 7,760 | 7,754 |
| Additional paid-in capital | 3,024,387 | 2,947,805 |
| Accumulated other comprehensive loss | (2,632) | (2,540) |
| Accumulated deficit | (2,483,583) | (2,294,159) |
Item 1. Financial Statements.
FAQ
- What is Summit Therapeutics's preferred stock, shares authorized?
- Summit Therapeutics (SMMT) reported preferred stock, shares authorized of $20M in Q1 2026.
- How has Summit Therapeutics's preferred stock, shares authorized changed year-over-year?
- Summit Therapeutics's preferred stock, shares authorized decreased by 0.0% year-over-year, from $20M to $20M.
- What is the long-term trend for Summit Therapeutics's preferred stock, shares authorized?
- Over 4 years (2021 to 2025), Summit Therapeutics's preferred stock, shares authorized has grown at a 0.0% compound annual growth rate (CAGR), from $20M to $20M.
Ask your AI about Summit Therapeutics's preferred stock, shares authorized.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude